Race Oncology Limited's (ASX:RAC) Daniel Tillett speaks to Proactive's Andrew Scott following the release of positive preclinical results for its Bisantrene drug in breast cancer. It was part of a collaborative research program between Race and The University of Newcastle with the aim of identifying combinations of current breast cancer drugs that when paired with Bisantrene show equivalent efficacy to existing treatment options, but with significantly reduced serious side effects.